KPV: reference dosing schedule
> Updated:
Calculate the KPV (Lys-Pro-Val) dose
The calculator is already set up for KPV (Lys-Pro-Val) — adjust the dose or diluent volume for your vial.
Human dosing
KPV dosing in the table below comes from community protocols and is a guide, not a clinical schedule: the dose steps up gradually from the starting amount to the upper bound of the cycle.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 200 mcg subcutaneously, once daily | Starting dose |
| Main regimen | 500 mcg subcutaneously, once daily | Increase if needed |
| Upper bound | up to 1 mg per day | Maximum in this schedule |
A full review of the mechanism and preclinical data is available in the monograph.
Practical dosing and effect details
KPV (Lys-Pro-Val) is a fragment of alpha-MSH, which is why research interest in it centers on anti-inflammatory activity. Kannengiesser and colleagues (Inflammatory Bowel Diseases, 2008) showed that giving KPV to mice with chemically induced colitis (a DSS model) sped recovery and reduced inflammatory tissue infiltration compared with controls. Those results come from mice and a model of intestinal inflammation, so they do not prove an effect from subcutaneous use in humans.
KPV is a tripeptide, one of the smallest molecules among the peptides on this site. There are no published human pharmacokinetic data for it. Preclinical work gave KPV orally: Dalmasso and colleagues (Gastroenterology, 2008) showed that the PepT1 transporter carries it into intestinal epithelial cells, and KPV in drinking water reduced DSS- and TNBS-induced colitis in mice. Topical KPV was tested in a mouse model of contact hypersensitivity and in corneal wound healing in rabbits. The subcutaneous route, daily dosing and 4–8 week cycles in the table come from community protocols, not from these studies.
This is reference information for planning a research protocol, not a medical recommendation and not instructions for self-administration.
How to reconstitute
An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.
- 1Add the diluentUse bacteriostatic water. Example: 2 ml into a 10 mg vial.KPV (Lys-Pro-Val)10 mg+ 2 mlDiluent
- 2Get the concentrationExample: 10 mg in 2 ml =KPV (Lys-Pro-Val)5 mg/ml(5,000 mcg/ml)
- 3Work out the volume per doseFor example, for a 0.2 mg dose:0.2 mg = 0.04 ml= 4 u. (U-100)
This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →
Research protocols
KPV: reference regimens
KPV (Lys-Pro-Val) is most often given subcutaneously once daily in community protocols; some figures are generalized from protocols that reconstitute it with bacteriostatic water. Cycles typically run 4–8 weeks. There are no published clinical studies of KPV in humans: the effect data come from animal and cell models.
More scientific background in the KPV (Lys-Pro-Val) monograph
Notes and safety
- • KPV (Lys-Pro-Val) is a research peptide. Human safety and efficacy data are limited.
- • The regimens shown are based on publications and research protocols, not clinical recommendations.
- • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
- • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
- • This information is for educational purposes and is not medical advice.
KPV (Lys-Pro-Val)